Previous close | 13.80 |
Open | 13.80 |
Bid | 13.00 |
Ask | 18.00 |
Strike | 82.50 |
Expiry date | 2024-01-19 |
Day's range | 13.80 - 13.80 |
Contract range | N/A |
Volume | |
Open interest | 22 |
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).